News | August 01, 2024
Ajanta Pharma posts Q1 FY25 consolidated PAT at Rs. 245.77 Cr
Ajanta Pharma has reported total income of Rs. 1,171.39 crores during the period ended June 30, 2024
Ajanta Pharma has reported total income of Rs. 1,171.39 crores during the period ended June 30, 2024
More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options
Dr. Jitendra Singh’s pioneering work on “Stress Diabetes in Kashmiri Migrants” was hailed by the World Health Organization
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
Fredun Pharmaceuticals has reported total income of Rs. 78.81 crores during the period ended June 30, 2024
Themis Medicare has reported total income of Rs. 123.95 crores during the period ended June 30, 2024
Granules India has reported total income of Rs. 1181.92 crores during the period ended June 30, 2024
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Pfizer Ltd. has reported total income of Rs. 604.70 crores during the period ended June 30, 2024
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
Subscribe To Our Newsletter & Stay Updated
